Cetihis Mechanism of Action

Pharmacotherapeutic group: Antihistamine (H₁-Receptor).
Pharmacology: In animals, Cetihis has been shown to be an anti-H₁ agent devoid of any significant anticholinergic or antiserotonin effects. At active doses, it does not induce sedation or behavioral changes.
Cetihis will inhibit certain effects produced by exogenous histamine. Cetihis also inhibits the effects produced by endogenous histamine released in vivo. It inhibits the cutaneous reaction induced by Vasoactive Intestinal Polypeptide and substance P. neuropeptides.
Cetihis inhibits the histamine-induced "early" phase of the allergic reaction. It also significantly reduces the migration of inflammatory cells e.g., eosinophils and the release of mediators associated with the "'late" allergic response.
Cetihis reduces bronchial hyper reactivity to histamine in the asthmatic patient. It also reduces the allergic reaction induced by specific allergens. These effects are obtained without any central effects.
Pharmacokinetics: Peak blood levels reached between 30 and 60 minutes after administration of 10 mg Cetihis. It is strongly bound to plasma proteins.